Literature DB >> 12559811

Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.

Bindu Sukumaran1, Poonam Tewary, Shailendra Saxena, Rentala Madhubala.   

Abstract

The gene ORFF is part of the multigenic LD1 locus on chromosome 35 that is frequently amplified in Leishmania. The function of ORFF is unknown. The gene encoding ORFF was cloned into a eukaryotic expression vector downstream to the cytomegalovirus (CMV) promoter. BALB/c mice were injected intramuscularly with ORFF DNA and challenged with Leishmania donovani promastigotes. Vaccination with ORFF gene induced both humoral and cellular immune response against ORFF, which provided significant level of protection against challenge with L. donovani. A qualitative PCR was used to determine whether activation of Th1 cells develops selectively in response to this ORFF DNA vaccine. The results indicated that mRNA for IFN-gamma was significantly induced in immunized mice. No significant change in IL-4 mRNA expression was observed in mice immunized with ORFF DNA vaccine versus mice immunized with control plasmid. Thus, DNA immunization may offer an attractive alternative strategy against leishmaniasis. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559811     DOI: 10.1016/s0264-410x(02)00352-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.

Authors:  Marie Breton; Michel J Tremblay; Marc Ouellette; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

2.  Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1.

Authors:  C Branger; B Chatrenet; A Gauvrit; F Aviat; A Aubert; J M Bach; G André-Fontaine
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Development of the Antileishmanial Vaccine.

Authors:  Sunil Kumar; Shubhranshu Zutshi; Mukesh Kumar Jha; Prashant Chauhan; Bhaskar Saha
Journal:  Methods Mol Biol       Date:  2022

4.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

5.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

6.  Vaccine Development Against Leishmania donovani.

Authors:  Amrita Das; Nahid Ali
Journal:  Front Immunol       Date:  2012-05-15       Impact factor: 7.561

7.  Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology.

Authors:  Michael Forgber; Rajatava Basu; Kaushik Roychoudhury; Stephan Theinert; Syamal Roy; Shyam Sundar; Peter Walden
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

8.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

9.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007

Review 10.  Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.

Authors:  Sumit Joshi; Keerti Rawat; Narendra Kumar Yadav; Vikash Kumar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.